Cancer Antigen (CA) 15-3 (Serial Monitor)
Also known as: CA 15-3
Use
The Cancer Antigen (CA) 15-3 test is designed for long-term serial monitoring of results in patients undergoing therapy for breast cancer. The test provides a color graphic summary report of CA 15-3 levels, which can assist in tracking the course of therapy. However, it is crucial to note that CA 15-3 levels obtained with different assay methods should not be used interchangeably. The test results should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Special Instructions
The account must submit the patient's Social Security number to enable monitoring services. Biotin interference can occur; patients should be instructed to discontinue biotin supplementation at least 72 hours before sample collection. Use test 143404 to order without the serial monitor service. Consistency in assay methods is recommended for ongoing monitoring.
Limitations
The assay may exhibit interference in samples from individuals consuming high doses of biotin, which can affect test results. Different assay methods or kits may yield non-comparable results, thus only one assay method should be used consistently to monitor a patient's therapy. Results cannot be solely interpreted for cancer presence or absence.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 6875-9
- 80563-0
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Patient Preparation
Stop biotin consumption at least 72 hours prior to collection.
Storage Instructions
Room temperature